hTERT Based Cancer Vaccine

As the most reliable technical supporter of vaccine researchers, Creative Biolabs has helped scientists around the world to complete their projects smoothly and efficiently in more than a decade, and we have developed unique insights and research platforms. We also have a large number of advanced technologies in the development of cancer vaccines. Developing a tumor vaccine with hTERT as a target is one of the novel and effective ideas.

hTERT and Its Potential in Developing a Cancer Vaccine

hTERT is an abbreviation for human telomerase reverse transcriptase, a catalytic subunit of telomerase. The end of the chromosome degrades after multiple rounds of replication, and telomerase can add a TTAGGG-like nucleic acid to the telomere at the end of the DNA strand to extend the telomeres of the DNA strand. Thus, those senescent cells that are going to undergo apoptosis will transcend the Heflik limit and become possible immortal cells, just like cancer cells. This function of telomerase and genomic association analysis indicate that the telomerase gene is a susceptibility gene for a variety of cancers. Its activity is related to the times of cell division and plays an important role in the immortality of cell lines such as cancer cells. Increased activity of telomerase is found in 90% of cancers. As a catalytically active subunit of telomerase, hTERT has therefore been extensively studied in cancer and tumorigenesis.

hTERT Based Cancer Vaccine

Based on the above facts, inhibition of the telomerase catalytic component hTERT to reduce the activity of the enzyme to cause cell death becomes a strategy for treating cancer. The additional advantage of this strategy is that normal cells do not express hTERT, so this therapy only causes tumor cells to age and apoptosis without affecting normal cells. Furthermore, in vitro studies have shown that hTERT peptide fragments can induce cytotoxic T cell responses against telomerase positive tumor cells.

Targeting hTERT, Creative Biolabs selects hTERT epitopes that have been recognized by the cancer patient's immune system. These epitopes have been shown to elicit strong T cell responses against different types of cancer. These epitopes include CD4 and CD8 epitopes, which are designed to exhibit hybridization in terms of vaccine HLA allelic types. Therefore, there is no need to pre-screen HLA for patients to allow vaccines to cover a broad population. Studies have demonstrated that vaccines that use these epitopes induce CD4⁺ T cell responses, which in turn produce Th1 cytokines, and provide inflammatory signals and helper T cells, all of which are key to triggering a powerful anti-tumor immune response.

Creative Biolabs is a professional vaccine development CRO that we have grown over the past decade and now our business covers all aspects of vaccine development and manufacturing. The design and development of tumor vaccines is one of our key points. We have conducted in-depth and extensive research on the prevention and treatment of tumors. The hTERT-based cancer vaccine is one of them.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.